Oncolytics Biotech Inc (ONCY)

Feb 19, 2025, 7:00 AM EST - 3 days ago

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

Feb 18, 2025, 7:00 AM EST - 4 days ago

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

Feb 14, 2025, 5:15 PM EST - 8 days ago

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Feb 7, 2025, 9:24 PM EST - 15 days ago

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

Jan 22, 2025, 7:00 AM EST - 4 weeks ago

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium

Jan 15, 2025, 7:02 AM EST - 5 weeks ago

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

Dec 23, 2024, 7:00 AM EST - 2 months ago

Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data

Dec 18, 2024, 7:00 AM EST - 2 months ago

Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium

Dec 3, 2024, 7:00 AM EST - 2 months ago

Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort

Nov 13, 2024, 9:01 PM EST - 3 months ago

Oncolytics Biotech Inc. (ONCY) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:00 AM EST - 3 months ago

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights

Nov 11, 2024, 7:00 AM EST - 3 months ago

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

Oct 4, 2024, 7:00 AM EDT - 5 months ago

Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path

Sep 19, 2024, 7:00 AM EDT - 5 months ago

Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

Sep 6, 2024, 8:00 AM EDT - 6 months ago

Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September

Aug 2, 2024, 7:00 AM EDT - 7 months ago

Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference

Aug 1, 2024, 7:55 PM EDT - 7 months ago

Oncolytics Biotech Inc. (ONCY) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:01 PM EDT - 7 months ago

Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights

Jul 24, 2024, 7:00 AM EDT - 7 months ago

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights

Jun 27, 2024, 7:00 AM EDT - 8 months ago

Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program

Jun 24, 2024, 7:00 AM EDT - 8 months ago

Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence

Jun 20, 2024, 7:26 AM EDT - 8 months ago

Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer

May 24, 2024, 7:00 AM EDT - 9 months ago

Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action

May 16, 2024, 7:00 AM EDT - 10 months ago

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

May 15, 2024, 7:00 AM EDT - 10 months ago

Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial

May 9, 2024, 8:48 PM EDT - 10 months ago

Oncolytics Biotech, Inc. (ONCY) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:01 PM EDT - 10 months ago

Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights

May 9, 2024, 7:00 AM EDT - 10 months ago

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

May 8, 2024, 7:00 AM EDT - 10 months ago

Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

Apr 30, 2024, 7:00 AM EDT - 10 months ago

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Apr 25, 2024, 7:00 AM EDT - 10 months ago

Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting

Apr 11, 2024, 7:00 AM EDT - 11 months ago

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

Apr 2, 2024, 7:00 AM EDT - 11 months ago

Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference

Mar 9, 2024, 1:09 AM EST - 1 year ago

Oncolytics Biotech, Inc. (ONCY) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 4:01 PM EST - 1 year ago

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Mar 6, 2024, 8:00 AM EST - 1 year ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

BLRX CADL IMRX

Mar 5, 2024, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN

Mar 4, 2024, 7:00 AM EST - 1 year ago

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Feb 28, 2024, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference

Feb 15, 2024, 8:00 AM EST - 1 year ago

Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments

Feb 14, 2024, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort

Jan 9, 2024, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors

Jan 4, 2024, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024

Dec 7, 2023, 7:00 AM EST - 1 year ago

Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS

Nov 9, 2023, 7:00 AM EST - 1 year ago

Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy

Nov 9, 2023, 6:30 AM EST - 1 year ago

Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep

Nov 3, 2023, 9:05 PM EDT - 1 year ago

Oncolytics Biotech Inc. (ONCY) Q3 2023 Earnings Call Transcript

Nov 3, 2023, 12:03 PM EDT - 1 year ago

Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC

Nov 3, 2023, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlights

Oct 23, 2023, 7:05 AM EDT - 1 year ago

Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO